A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up Meeting Abstract
| Authors: | Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; Litzow, M. R.; Lin, T. L.; Patel, P. A.; Foster, M. C.; Boyiadzis, M. M.; Collins, R. H.; Chervin, J.; Shoben, A. B.; Vergilio, J. A.; Heerema, N. A.; Rosenberg, L.; Chen, T.; Yocum, A. O.; Druggan, F.; Marcus, S.; Stefanos, M.; Martycz, M.; Druker, B. J.; Mims, A. S.; Borate, U.; Burd, A.; Byrd, J. C.; Levine, R. L. |
| Abstract Title: | A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 2016 |
| End Page: | 2019 |
| Language: | English |
| ACCESSION: | WOS:000893223202009 |
| DOI: | 10.1182/blood-2022-166850 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
